lesions from patients with erythrodermic psoriasis) and from the control group (HC
peripheral blood and non-lesions from patients with erythrodermic psoriasis) were
added to 11 separate 1.5 mL Eppendorf tubes. For both groups, one tube was used as a
negative control, and to the other 7 tubes were added 2 µL mouse anti human
FITC-labeled CD19, PE-labeled CD40, APC-labeled CD44, PE-labeled CD80, APC-labeled
CD86, PE-labeled CD11b, and APC-labeled HLA-DR monoclonal antibodies (BD Biosciences,
USA). A mixture of 2 µL FITC-labeled CD19, 2 µL PE-labeled CD40, and 2 µL APC-labeled
CD44 was added to the ninth tube. In the tenth tube, 2 µL FITC-labeled CD19, 2 µL
PE-labeled CD80, and 2 µL APC-labeled CD86 was added. In a final tube, 2 µL
FITC-labeled CD19, 2 µL PE-labeled CD11b, and 2 µL APC-labeled HLA-DR was added. The
samples were then placed at 4°C for 30 min in dark. After that, the samples were
washed with PBS twice, and centrifuged at 729 g (4°C) for 5 min
between washes. The supernatant was removed and the cell pellet was analyzed using an
ACS Calibur flow cytometer (BD Biosciences, the process strictly complied the
guidelines of the equipment).